These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 22587443

  • 1. Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.
    Takahashi Y, Hibi S, Hoshino Y, Kikuchi K, Shin K, Murata-Tai K, Fujisawa M, Ino M, Shibata H, Yonaga M.
    J Med Chem; 2012 Jun 14; 55(11):5255-69. PubMed ID: 22587443
    [Abstract] [Full Text] [Related]

  • 2. Design, synthesis, and structure-activity relationships of novel pyrazolo[5,1-b]thiazole derivatives as potent and orally active corticotropin-releasing factor 1 receptor antagonists.
    Takahashi Y, Hashizume M, Shin K, Terauchi T, Takeda K, Hibi S, Murata-Tai K, Fujisawa M, Shikata K, Taguchi R, Ino M, Shibata H, Yonaga M.
    J Med Chem; 2012 Oct 11; 55(19):8450-63. PubMed ID: 22971011
    [Abstract] [Full Text] [Related]

  • 3. Selective corticotropin-releasing factor 1 receptor antagonist E2508 has potent antidepressant-like and anxiolytic-like properties in rodent models.
    Taguchi R, Shikata K, Furuya Y, Ino M, Shin K, Shibata H.
    Behav Brain Res; 2016 Oct 01; 312():138-47. PubMed ID: 27297028
    [Abstract] [Full Text] [Related]

  • 4. Potent, orally active corticotropin-releasing factor receptor-1 antagonists containing a tricyclic pyrrolopyridine or pyrazolopyridine core.
    Dyck B, Grigoriadis DE, Gross RS, Guo Z, Haddach M, Marinkovic D, McCarthy JR, Moorjani M, Regan CF, Saunders J, Schwaebe MK, Szabo T, Williams JP, Zhang X, Bozigian H, Chen TK.
    J Med Chem; 2005 Jun 16; 48(12):4100-10. PubMed ID: 15943483
    [Abstract] [Full Text] [Related]

  • 5. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
    Chen YL, Braselton J, Forman J, Gallaschun RJ, Mansbach R, Schmidt AW, Seeger TF, Sprouse JS, Tingley FD, Winston E, Schulz DW.
    J Med Chem; 2008 Mar 13; 51(5):1377-84. PubMed ID: 18260619
    [Abstract] [Full Text] [Related]

  • 6. Design and synthesis of tricyclic corticotropin-releasing factor-1 antagonists.
    Gross RS, Guo Z, Dyck B, Coon T, Huang CQ, Lowe RF, Marinkovic D, Moorjani M, Nelson J, Zamani-Kord S, Grigoriadis DE, Hoare SR, Crowe PD, Bu JH, Haddach M, McCarthy J, Saunders J, Sullivan R, Chen T, Williams JP.
    J Med Chem; 2005 Sep 08; 48(18):5780-93. PubMed ID: 16134945
    [Abstract] [Full Text] [Related]

  • 7. Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists.
    Wilcoxen K, Huang CQ, McCarthy JR, Grigoriadis DE, Chen C.
    Bioorg Med Chem Lett; 2003 Oct 06; 13(19):3367-70. PubMed ID: 12951127
    [Abstract] [Full Text] [Related]

  • 8. Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists.
    Huang CQ, Wilcoxen K, McCarthy JR, Haddach M, Grigoriadis D, Chen C.
    Bioorg Med Chem Lett; 2003 Oct 06; 13(19):3371-4. PubMed ID: 12951128
    [Abstract] [Full Text] [Related]

  • 9. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.
    Koike T, Takai T, Hoashi Y, Nakayama M, Kosugi Y, Nakashima M, Yoshikubo S, Hirai K, Uchikawa O.
    J Med Chem; 2011 Jun 23; 54(12):4207-18. PubMed ID: 21568291
    [Abstract] [Full Text] [Related]

  • 10. Design and synthesis of tricyclic imidazo[4,5-b]pyridin-2-ones as corticotropin-releasing factor-1 antagonists.
    Guo Z, Tellew JE, Gross RS, Dyck B, Grey J, Haddach M, Kiankarimi M, Lanier M, Li BF, Luo Z, McCarthy JR, Moorjani M, Saunders J, Sullivan R, Zhang X, Zamani-Kord S, Grigoriadis DE, Crowe PD, Chen TK, Williams JP.
    J Med Chem; 2005 Aug 11; 48(16):5104-7. PubMed ID: 16078829
    [Abstract] [Full Text] [Related]

  • 11. Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
    Gilligan PJ, Clarke T, He L, Lelas S, Li YW, Heman K, Fitzgerald L, Miller K, Zhang G, Marshall A, Krause C, McElroy JF, Ward K, Zeller K, Wong H, Bai S, Saye J, Grossman S, Zaczek R, Arneric SP, Hartig P, Robertson D, Trainor G.
    J Med Chem; 2009 May 14; 52(9):3084-92. PubMed ID: 19361209
    [Abstract] [Full Text] [Related]

  • 12. 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists.
    Chen YL, Obach RS, Braselton J, Corman ML, Forman J, Freeman J, Gallaschun RJ, Mansbach R, Schmidt AW, Sprouse JS, Tingley Iii FD, Winston E, Schulz DW.
    J Med Chem; 2008 Mar 13; 51(5):1385-92. PubMed ID: 18288792
    [Abstract] [Full Text] [Related]

  • 13. Selective corticotropin-releasing factor 1 receptor antagonist E2508 reduces restraint stress-induced defecation and visceral pain in rat models.
    Taguchi R, Shikata K, Furuya Y, Hirakawa T, Ino M, Shin K, Shibata H.
    Psychoneuroendocrinology; 2017 Jan 13; 75():110-115. PubMed ID: 27810704
    [Abstract] [Full Text] [Related]

  • 14. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ, Wilcoxen KM, Grigoriadis DE, McCarthy JR, Chen C.
    Bioorg Med Chem Lett; 2004 Aug 02; 14(15):3943-7. PubMed ID: 15225703
    [Abstract] [Full Text] [Related]

  • 15. Imidazo[4,5-c]pyridines as corticotropin releasing factor receptor ligands.
    Arvanitis AG, Rescinito JT, Arnold CR, Wilde RG, Fitzgerald LW, Zaczek R, Hartig PR, Grossman S, Arneric SP, Gilligan PJ, Olson RE, Robertson DW.
    Bioorg Med Chem Lett; 2003 Jan 06; 13(1):129-31. PubMed ID: 12467632
    [Abstract] [Full Text] [Related]

  • 16. Synthesis and structure-activity relationships of 8-substituted-2-aryl-5-alkylaminoquinolines: Potent, orally active corticotropin-releasing factor-1 receptor antagonists.
    Takeda K, Terauchi T, Hashizume M, Shikata K, Taguchi R, Murata-Tai K, Fujisawa M, Takahashi Y, Shin K, Ino M, Shibata H, Yonaga M.
    Bioorg Med Chem; 2012 Nov 15; 20(22):6559-78. PubMed ID: 23062820
    [Abstract] [Full Text] [Related]

  • 17. Discovery of NBI-77860/GSK561679, a potent corticotropin-releasing factor (CRF1) receptor antagonist with improved pharmacokinetic properties.
    Tellew JE, Lanier M, Moorjani M, Lin E, Luo Z, Slee DH, Zhang X, Hoare SR, Grigoriadis DE, St Denis Y, Di Fabio R, Di Modugno E, Saunders J, Williams JP.
    Bioorg Med Chem Lett; 2010 Dec 15; 20(24):7259-64. PubMed ID: 21074436
    [Abstract] [Full Text] [Related]

  • 18. Novel pyrazolo[1,5-a]pyridines as orally active EP1 receptor antagonists: Synthesis, structure-activity relationship studies, and biological evaluation.
    Umei K, Nishigaya Y, Kondo A, Tatani K, Tanaka N, Kohno Y, Seto S.
    Bioorg Med Chem; 2017 May 01; 25(9):2635-2642. PubMed ID: 28342692
    [Abstract] [Full Text] [Related]

  • 19. Synthesis, structure-activity relationships and biological evaluation of 4,5,6,7-tetrahydropyrazolopyrazines as metabotropic glutamate receptor 5 negative allosteric modulators.
    Hirose W, Kato Y, Yamamoto T, Kassai M, Takata M, Hayashi S, Arai Y, Imai S, Yoshida K.
    Bioorg Med Chem Lett; 2016 Aug 15; 26(16):3866-9. PubMed ID: 27432763
    [Abstract] [Full Text] [Related]

  • 20. 6,7-Dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidines and their derivatives as novel corticotropin-releasing factor 1 receptor antagonists.
    Saito T, Obitsu T, Kondo T, Matsui T, Nagao Y, Kusumi K, Matsumura N, Ueno S, Kishi A, Katsumata S, Kagamiishi Y, Nakai H, Toda M.
    Bioorg Med Chem; 2011 Sep 15; 19(18):5432-45. PubMed ID: 21865047
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.